Therefore, the aim of this study was to analyze whether CD163 can be used as a marker for TAMs and to compare its prognostic value with the more frequently used pan-macrophage marker CD68 in a tissue microarray (TMA) with tumors from 144 breast cancer patients. Here, CD163 is linked to breast carcinoma.